Abstract
The objective of this work was to develop tablet formulations of nimesulide-β-cyclodextrin (NI-β-CD) and meloxicam-γ-cyclodextrin (ME-γ-CD) binary systems. In the case of nimesulide, 3 types of binary systems—physical mixtures, kneaded systems, and coevaporated systems—were studied. In the case of meloxicam, 2 types of binary systems—physical mixtures and kneaded systems—were investigated. Both drug-CD binary systems were prepared at 1∶1 and 1∶2 molar ratio (1∶1M and 1∶2M) and used in formulation studies. The tablet formulations containing drug-CD binary systems prepared by the wet granulation and direct compression methods showed superior dissolution properties when compared with the formulations of the corresponding pure drug formulations. Overall, the dissolution properties of tablet formulations prepared by the direct compression method were superior to those of tablets prepared by the wet granulation method. Selected tablet formulations showed good stability with regard to drug content, disintegration time, hardness, and in vitro dissolution properties over 6 months at 40°C±2°C and 75% relative humidity.
Keywords: Nimesulide, meloxicam, cyclodextrins, tablet formulations, dissolution properties, stability studies
Full Text
The Full Text of this article is available as a PDF (163.1 KB).
References
- 1.Duchene D, Wouessidjewe D. Pharmaceutical uses of cyclodextrins and derivatives. Drug Dev Ind Pharm. 1990;16:2487–2499. doi: 10.3109/03639049009058543. [DOI] [Google Scholar]
- 2.Bekers O, Uijtendal EV, Beijnen JH, Bult A, Underberg WJ. Cyclodextrins in pharmaceutical field. Drug Dev. Ind Pharm. 1991;17:1503–1549. doi: 10.3109/03639049109026630. [DOI] [Google Scholar]
- 3.Davis R, Brogden RN. Nimesulide: an update of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy. Drugs. 1994;48:431–454. doi: 10.2165/00003495-199448030-00008. [DOI] [PubMed] [Google Scholar]
- 4.Engelhardt G, Homma D, Schlegel K, Schnitzeler C, Utzmann R. Anti inflammatory, analgesic, antipyretic and related properties of meloxicam, a new nonsteroidal anti inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res. 1995;44:423–433. doi: 10.1007/BF01757699. [DOI] [PubMed] [Google Scholar]
- 5.Engelhardt G, Bogel R, Schnitzeler C, Utzmann R. Meloxicam: influence on arachidonic acid metabolism. Part 1: in vitro findings. Biochem Pharmacol. 1996;51:21–28. doi: 10.1016/0006-2952(95)02111-6. [DOI] [PubMed] [Google Scholar]
- 6.Churchill L, Graham AG, Shih CK, Pauletti D, Farina PR, Grob PM. Selective inhibition of human cyclooxygenase-2 by meloxicam. Inflammopharmacology. 1996;4:125–135. doi: 10.1007/BF02735467. [DOI] [Google Scholar]
- 7.Pairet M, Engelhardt G. Differential inhibition of COX-1 and COX-2 in vitro and pharmacological profile in vivo of NSAIDs. In: Vane J, Botting J, Botting R, editors. Improved Nonsteroidal Anti-inflammatory Drugs-COX-2 Enzyme Inhibitors. Dordrecht, The Netherlands: Kluwer Academic Publishers; 1996. pp. 103–119. [Google Scholar]
- 8.Distel M, Mueller C, Bluhmki E. Global analysis of gastrointestinal safety of a new NSAID, meloxicam. Inflammopharmacology. 1996;4:71–81. doi: 10.1007/BF02735561. [DOI] [Google Scholar]
- 9.Turck D, Busch U, Heinzel G, Narjes H. Clinical pharmacokinetics of meloxicam. Arzneimittelforschung. 1997;47:253–258. [PubMed] [Google Scholar]
- 10.Piel G, Pirotte B, Delneuveille I, et al. Study of the influence of both cyclodextrins and L-lysine on the aqueous solubility of nimesulide; isolation and characterization of nimesulide-L-lysine-cyclodextrin complexes. J Pharm Sci. 1997;86:475–480. doi: 10.1021/js960298k. [DOI] [PubMed] [Google Scholar]
- 11.Nalluri BN, Chowdary KPR, Murthy KV, Hayman AR, Becket G. Physicochemical characterization and dissolution properties of nimesulide-cyclodextrin binary systems. AAPS PharmSciTech. 2003;4:E2–E2. doi: 10.1208/pt040102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Naidu NB, Chowdary KP, Murthy KV, Satyanarayana V, Hayman AR, Becket G. Physicochemical characterization and dissolution properties of meloxicam-cyclodextrin binary systems. J Pharm Biomed Anal. 2004;35:75–86. doi: 10.1016/j.jpba.2004.01.003. [DOI] [PubMed] [Google Scholar]
- 13.Bodmeier R, Paerataku O. Constant potassium chloride release from microporous membrane-coated tablets prepared with aqueous colloidal polymer dispersions. Pharm Res. 1991;8:355–359. doi: 10.1023/A:1015897616351. [DOI] [PubMed] [Google Scholar]
- 14.Khan KA. The concept of dissolution efficiency. J Pharm Pharmacol. 1975;27:48–49. doi: 10.1111/j.2042-7158.1975.tb09378.x. [DOI] [PubMed] [Google Scholar]
- 15.Carstensen JT. Stability and dating of solid dosage forms. In: Carstensen JT, editor. Pharmaceutics of Solids and Solid Dosage Forms. New York, NY: Wiley-Interscience; 1997. pp. 182–185. [Google Scholar]